8G2M

The tumor activated anti-CTLA-4 monoclonal antibody XTX101 demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

8G2M の概要

• エントリーDOI: 10.2210/pdb8g2m/pdb
• 分子名称: masking peptide, Heavy chain of humanized IgG, Light chain of humanized IgG, ... (5 entities in total)
• 機能のキーワード: engineered antibody, immune system
• 由来する生物種: Mus musculus; 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 47103.47

構造登録者

Williams, J.C.,Williams, J.C. (登録日: 2023-02-05, 公開日: 2024-02-14, 最終更新日: 2024-10-30)

主引用文献

Jenkins, K.A.,Park, M.,Pederzoli-Ribeil, M.,Eskiocak, U.,Johnson, P.,Guzman, W.,McLaughlin, M.,Moore-Lai, D.,O'Toole, C.,Liu, Z.,Nicholson, B.,Flesch, V.,Qiu, H.,Clackson, T.,O'Hagan, R.C.,Rodeck, U.,Karow, M.,O'Neil, J.,Williams, J.C.
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
J Immunother Cancer, 11:-, 2023

PubMed Abstract: The clinical benefit of the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab has been well established but limited by immune-related adverse events, especially when ipilimumab is used in combination with anti-PD-(L)1 mAb therapy. To overcome these limitations, we have developed XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 mAb.

PubMed: 38164757
DOI: 10.1136/jitc-2023-007785

実験手法

X-RAY DIFFRACTION (1.8 Å)